Syndax Pharma (SNDX) revealed Loss for fourth quarter of -$68.01 million
The company's bottom line came in at -$68.01 million, or -$0.78 per share. This compares with -$94.17 million, or -$1.10 per share, last year.
The company's revenue for the period rose 794.9% to $68.73 million from $7.68 million last year.
Syndax Pharma earnings at a glance (GAAP) :
-Earnings: -$68.01 Mln. vs. -$94.17 Mln. last year.-EPS: -$0.78 vs. -$1.10 last year.-Revenue: $68.73 Mln vs. $7.68 Mln last year.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.